Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183960

2024-01-01

Abstract:Supplementary Table S4. Primers used for qPCR or generating knockout/knockdown constructs.

What problem does this paper attempt to address?

Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191539

2024-01-01

Abstract:Supplementary Table S2. Detailed information of human pancreatic tissue array.
Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191542

2024-01-01

Abstract:Supplementary Table S1. MAGeCK analysis of CRISPR screen results to identify regulator of immune evasion in orthotopic PDAC mouse models.
SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhaobo Liu,Lang Chen,Yimin Fang,Pingping Ma,Xiaochong Wu,Hao Kong,Wenting Liao,Jingping Hong,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183972

2024-01-01

Abstract:Supplementary Figure S1. In vivo CRISPR screens to identify critical drivers of immune evasion; Supplementary Figure S2. Effects of Ripk2 depletion on tumor growth; Supplementary Figure S3. RIPK2 is overexpressed in human and mouse PDAC tissues; Supplementary Figure S4. Ablation of RIPK2 disrupts the desmoplastic TME; Supplementary Figure S5. RIPK2 modulates the immune profile and impairs anti-tumor T cell response; Supplementary Figure S6. RIPK2 restricts the activation and effector states of CD8+ T cells by impairing antigen presentation; Supplementary Figure S7. RIPK2 promotes MHC-I trafficking to lysosomes via NBR1; Supplementary Figure S8. RIPK2 ubiquitination promotes NBR1-mediated MHC-I degradation; Supplementary Figure S9. RIPK2 ablation potentiates the efficacy of PD-1 blockade; Supplementary Figure S10. Diagram illustrating RIPK2-mediated degradation of MHC I through autophagy–lysosome system.
Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation

Chongbiao Huang,Yang Li,Zengxun Li,Yang Xu,Na Li,Yi Ge,Jie Dong,Antao Chang,Tiansuo Zhao,Xiuchao Wang,Hongwei Wang,Shengyu Yang,Keping Xie,Jihui Hao,He Ren

DOI: https://doi.org/10.1158/1078-0432.22470555

2023-01-01

Abstract:7 Supplementary Tables: Supplementary Table S1. Association between LIMS1 expression and clinicopathological features of patients with PDAC. Supplementary Table S2. Association between LIMS1 mRNA expression and clinicopathological features of PDAC patients from TCGA. Supplementary Table S3. Cox's proportional hazards model analysis of prognostic factors in patients with pancreatic ductal adenocarcinoma (PDAC) Supplementary Table S4. Association between LIMS1 expression and clinicopathological features of patients with esophageal cancer. Supplementary Table S5. Association between LIMS1 expression and clinicopathological features of patients with lung adenocarcinoma. Supplementary Table S6. Main antibodies and reagents. Supplementary Table S7. Primers and oligonucleotides sequences.
Data from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.cd-23-0584

IF: 28.2

2024-01-01

Cancer Discovery

Abstract:AbstractPancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy because of its aggressive nature and the paucity of effective treatment options. Almost all registered drugs have proven ineffective in addressing the needs of patients with PDAC. This is the result of a poor understanding of the unique tumor–immune microenvironment (TME) in PDAC. To identify druggable regulators of immunosuppressive TME, we performed a kinome- and membranome-focused CRISPR screening using orthotopic PDAC models. Our data showed that receptor-interacting protein kinase 2 (RIPK2) is a crucial driver of immune evasion of cytotoxic T-cell killing and that genetic or pharmacologic targeting of RIPK2 sensitizes PDAC to anti–programmed cell death protein 1 (anti–PD-1) immunotherapy, leading to prolonged survival or complete regression. Mechanistic studies revealed that tumor-intrinsic RIPK2 ablation disrupts desmoplastic TME and restores MHC class I (MHC-I) surface levels through eliminating NBR1-mediated autophagy-lysosomal degradation. Our results provide a rationale for a novel combination therapy consisting of RIPK2 inhibition and anti–PD-1 immunotherapy for PDAC.Significance:PDAC is resistant to almost all available therapies, including immune checkpoint blockade. Through in vivo CRISPR screen, we identified that RIPK2 plays a crucial role in facilitating immune evasion by impeding antigen presentation and cytotoxic T-cell killing. Targeting tumor-intrinsic RIPK2 either genetically or pharmacologically improves PDAC to anti–PD-1 immunotherapy.See related commentary by Liu et al., p. 208.This article is featured in Selected Articles from This Issue, p. 201
Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Hong Zheng,Weipeng Zhao,Cihui Yan,Crystina C. Watson,Michael Massengill,Mengyu Xie,Chris Massengill,David R. Noyes,Gary V. Martinez,Roha Afzal,Zhihua Chen,Xiubao Ren,Scott J. Antonia,Eric B. Haura,Brian Ruffell,Amer A. Beg

DOI: https://doi.org/10.1158/1078-0432.22454714

2023-01-01

Abstract:Supplementary Table 2. Probe sets showing 2-fold difference in expression in 2 independent experiments with romidepsin treatment of LKR. Probe sets with very low expression (cutoff of <100 under all tested conditions) were removed. Probe set ID, direction of change after romidepsin treatment, accession number and gene symbol when available are indicated.
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Receptor-interacting protein kinase 2 is an immunotherapy target in pancreatic cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu,Chengxuan YU

DOI: https://doi.org/10.1158/2159-8290.cd-23-0584

IF: 28.2

2023-10-14

Cancer Discovery

Abstract:Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancies due to its aggressive nature and the paucity of effective treatment options. Almost all registered drugs have proven ineffective in addressing the needs of PDAC patients. This is the result of a poor understanding of the unique tumor immune microenvironment (TME) in PDAC. To identify druggable regulators of immunosuppressive TME, we performed a kinome- and membranome-focused CRISPR screening using orthotopic PDAC models. Our data showed that RIPK2 is a crucial driver of immune evasion of cytotoxic T-cell killing and that genetic or pharmacological targeting of RIPK2 sensitizes PDAC to anti-PD-1 immunotherapy, leading to prolonged survival or complete regression. Mechanistic studies revealed that tumor-intrinsic RIPK2 ablation disrupts desmoplastic TME and restores MHC-I surface levels through eliminating NBR1-mediated autophagy-lysosomal degradation. Our results provide a rationale for a novel combination therapy consisting of RIPK2 inhibition and anti-PD-1 immunotherapy for PDAC.

oncology
Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Qing Cao,Zhengshuai Song,Hailong Ruan,Cheng Wang,Yan Xiong,Bingcheng Lin,Keshan Wang,Gong Chen,Tianbo Xu,Wen Xu,Xiong Zhang,Di Liu,Ming–Hsuan Yang,Diwei Zhou,Hongmei Yang,Ke Chen,Xiaoping Zhang

DOI: https://doi.org/10.1158/1078-0432.22473300.v1

2023-01-01

Abstract:Primers used in quantitative polymerase chain reaction for analysis of genomic amplification
Supplementary Table S2 from an Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma

Mao Zhang,Yingying Huang,Jiaomeng Pan,Chen Sang,Youpei Lin,Liangqing Dong,Xia Shen,Yingcheng Wu,Guohe Song,Shuyi Ji,Fen Liu,Mengcheng Wang,Yuyan Zheng,Sirui Zhang,Zefeng Wang,Jianke Ren,Daming Gao,Jian Zhou,Jia Fan,Wu Wei,Jian Lin,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.24249146.v1

2023-01-01

Abstract:Supplementary Table S2. Differential ASEs, primers and sequences information.
Supplementary Table S1 from an Inflammatory Checkpoint Generated by <i>il1rn</i> Splicing Offers Therapeutic Opportunity for &Lt;i>kras</i>-Mutant Intrahepatic Cholangiocarcinoma

Mao Zhang,Yingying Huang,Jiaomeng Pan,Chen Sang,Youpei Lin,Liangqing Dong,Xia Shen,Yingcheng Wu,Guohe Song,Shuyi Ji,Fen Liu,Mengcheng Wang,Yuyan Zheng,Sirui Zhang,Zefeng Wang,Juanjuan Ren,Daming Gao,Jian Zhou,Jia Fan,Wei Wu,Jian Lin,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.24249149

2023-01-01

Abstract:Supplementary Table S1. Samples and transcriptomics information.
Supplementary Table 1 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Ling Li,Wenhua Tang,Xiaoqing Wu,David Karnak,Xiaojie Meng,Rachel Thompson,Xinbao Hao,Yongmin Li,Xiaotan T. Qiao,Jiayuh Lin,James Fuchs,Diane M. Simeone,Zhi-Nan Chen,Theodore S. Lawrence,Liang Xu

DOI: https://doi.org/10.1158/1078-0432.22446368.v1

2023-01-01

Abstract:PDF file - 112K, The sequences of the oligonucleotide primers used for qPCR (related to the qRT-PCR section of Materials and Methods).
Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Jiang Chen,Zohreh Amoozgar,Xin Liu,Shuichi Aoki,Zelong Liu,Sarah M. Shin,Aya Matsui,Alexei Hernandez,Zhangya Pu,Stefan Halvorsen,Pin-Ji Lei,Meenal Datta,Lingling Zhu,Zhiping Ruan,Lei Shi,Daniel Staiculescu,Koetsu Inoue,Lance L. Munn,Dai Fukumura,Peigen Huang,Slim Sassi,Nabeel Bardeesy,Won Jin Ho,Rakesh K. Jain,Dan G. Duda

DOI: https://doi.org/10.1158/2326-6066.25523060.v1

2024-01-01

Abstract:Supplementary Table S3: IMC panel.
Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419831

2023-01-01

Abstract:Supplementary Table S1. Primers for qRT-PCR and MSP
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
Supplementary Table I and II from PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

Nisha Nagarsheth,Dongjun Peng,Ilona Kryczek,Ke Wu,Wei Li,Ende Zhao,Lili Zhao,Shuang Wei,Timothy Frankel,Linda Vatan,Wojciech Szeliga,Yali Dou,Scott Owens,Victor Marquez,Kaixiong Tao,Emina Huang,Guobin Wang,Weiping Zou

DOI: https://doi.org/10.1158/0008-5472.22409408.v1

2023-01-01

Abstract:This is Supplementary Tables I and II Table 1: RT-PCR primers and ChIP primers Table 2: shRNA Sequences
Supplemental Tables from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Hong Zhu,Dan-Dan Wang,Tao Yuan,Fang-Jie Yan,Chen-Ming Zeng,Xiao-Yang Dai,Zi-bo Chen,Ying Chen,Tianyi Zhou,Guang-Han Fan,Meidan Ying,Ji Cao,Peihua Luo,Xi-Jie Liu,Yuandong Hu,Yong Peng,Qiaojun He,Bo Yang

DOI: https://doi.org/10.1158/0008-5472.22417223.v1

2023-01-01

Abstract:Supplemental Table 1. The primer sequences for qRT-PCR assay Supplemental Table 2. The targeting sequences for siRNA Supplemental Table 3. The list of compounds for YAP-TEADs luciferase screening
Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964573.v1

2024-01-01

Abstract:The Supplementary Data consist of: Supplementary Tables S1-7
Supplementary Tables 1-7 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Chen Liang,Yi Qin,Bo Zhang,Shunrong Ji,Si Shi,Wenyan Xu,Jiang Liu,Jinfeng Xiang,Dingkong Liang,Qiangsheng Hu,Quanxing Ni,Jin Xu,Xianjun Yu

DOI: https://doi.org/10.1158/1541-7786.22512169

2023-01-01

Abstract:Supplementary Table S1. Primers sequences used in the real-time PCR. Supplementary Table S2. siRNA oligoes used in the study. Supplementary Table S3. Primers sequences used in the quantitative ChIP. Supplementary Table S4. Clinicopathological features and correlation of MUC16 expression in PDAC in the TCGA cohorts. Supplementary Table S5. Univariate and multivariate Cox regression of Overall survival for patients with PDAC in the TCGA cohorts. Supplementary Table S6. Clinicopathological features and correlation of MUC16 expression in PDAC in the FUSCC cohorts. Supplementary Table S7. Univariate and multivariate Cox regression of Overall survival for patients with PDAC in the FUSCC cohorts.
Supplementary Table S1 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Yong Li,Shunqun Luo,Ruihua Ma,Jing Liu,Pingwei Xu,Huafeng Zhang,Ke Tang,Jingwei Ma,Yi Zhang,Xiaoyu Liang,Yanling Sun,Tiantian Ji,Ning Wang,Bo Huang

DOI: https://doi.org/10.1158/0008-5472.22409990.v1

2023-01-01

Abstract:Supplementary Table S1. List of RT-PCR primers used.

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation

Data from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Receptor-interacting protein kinase 2 is an immunotherapy target in pancreatic cancer

Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Table S2 from an Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma

Supplementary Table S1 from an Inflammatory Checkpoint Generated by &lt;i&gt;il1rn&lt;/i&gt; Splicing Offers Therapeutic Opportunity for &Lt;i&gt;kras&lt;/i&gt;-Mutant Intrahepatic Cholangiocarcinoma

Supplementary Table 1 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Table I and II from PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

Supplemental Tables from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Tables 1-7 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Supplementary Table S1 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Supplementary Table S1 from an Inflammatory Checkpoint Generated by <i>il1rn</i> Splicing Offers Therapeutic Opportunity for &Lt;i>kras</i>-Mutant Intrahepatic Cholangiocarcinoma